Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J9UB
|
|||
| Former ID |
DNCL002463
|
|||
| Drug Name |
RG7593
|
|||
| Indication | Haematological malignancy [ICD-11: 2B33.Y] | Discontinued in Phase 2 | [1] | |
| Company |
Seattle Genetics; Roche
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-cell receptor CD22 (CD22) | Target Info | Modulator | [2] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Hematopoietic cell lineage | ||||
| B cell receptor signaling pathway | ||||
| Panther Pathway | B cell activation | |||
| Pathway Interaction Database | BCR signaling pathway | |||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | ||||
| WikiPathways | B Cell Receptor Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027651) | |||
| REF 2 | Clinical pipeline report, company report or official report of Roche. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.